ONCOLYTICS BIOTECH INC. Operating Lease Cost
ONCOLYTICS BIOTECH INC. (ONCY) reported Operating Lease Cost of $71.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-12
- ONCOLYTICS BIOTECH INC. operating lease, cost for the quarter ending 2026-06-30 was $71.00K, a 1.39% decline year-over-year.
- ONCOLYTICS BIOTECH INC. operating lease, cost for the quarter ending 2026-03-31 was $73.00K, a 0.00% change year-over-year.
- ONCOLYTICS BIOTECH INC. operating lease, cost for the quarter ending 2025-06-30 was $72.00K.
- ONCOLYTICS BIOTECH INC. operating lease, cost for the quarter ending 2025-03-31 was $73.00K.
- ONCOLYTICS BIOTECH INC. operating lease, cost for fiscal 2025 was $288.00K, a 3.03% decline from fiscal 2024.
- ONCOLYTICS BIOTECH INC. operating lease, cost for fiscal 2024 was $297.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 12 month |
|---|---|---|---|
| 2026-06-30 | $71.00K 10-Q · filed 2026-08-12 | $144.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $73.00K 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $288.00K 10-K · filed 2026-03-30 | ||
| 2025-06-30 | $72.00K 10-Q · filed 2026-08-12 | $145.00K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $73.00K 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $297.00K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |